论文部分内容阅读
Sorafenib is an oral multi-kinase inhibitor and represents a major breakthrough in thetherapy of advanced hepatocellular carcinoma.However, the mechanisms of Sorafenibmediated-antitumor affects in HCC have not been fully elucidated.AIB1 is frequently overexpressedin human HCC tissues and promotes hepatocellular carcinoma progression.